Prevention of Renal Damage in Murine Lupus Nephritis by CTLA-4Ig and Cyclophosphamide

Arthritis and Rheumatism

Volumn 50, Issue 5, 2004, Pages 1539-1548

  Cunnane, Gaye ^a   Chan, Owen T M ^a   Cassafer, Gail ^a   Brindis, Seth ^a   Kaufman, Elizabeth ^a   Yen, T S Benedict ^a   Daikh, David I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 IMMUNOGLOBULIN; IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SELECTION; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG SCREENING; FEMALE; FLUORESCENCE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPROPHYLAXIS; KIDNEY INJURY; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ANIMALS; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; B-LYMPHOCYTES; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; IMMUNOSUPPRESSIVE AGENTS; KIDNEY GLOMERULUS; LUPUS NEPHRITIS; MICE; MICE, INBRED STRAINS; PROTEINURIA; T-LYMPHOCYTES;

EID: 2342495275     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20147     Document Type: Article

References (28)

1. Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 2001;166:2913-6.
2. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 1991;174:561-9.
3. Hahn BH, Knotts L, Ng M, Hamilton TR. Influence of cyclophosphamide and other immunosuppressive drugs on immune disorders and neoplasia in NZB/NZW mice. Arthritis Rheum 1975;18:145-52.
4. Walker SE, Anver MR. Stimulated autoantibody response and increased longevity in NZB/NZW mice treated with cyclophosphamide and tilorone. Clin Exp Immunol 1978;33:453-62.
5. Wofsy D, Seaman WE. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J Exp Med 1985;161:378-91.
6. Balow JE, Austin HA III, Muenz LR, Joyce KM, Antonovych TT, Klippel JH, et al. Effect of treatment on the evolution of renal abnormalities in lupus nephritis. N Engl J Med 1984;311:491-5.
7. Austin HA III, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984;25:689-95.
8. Hicks JD, Burnet FM. Renal lesions in the "auto-immune" mouse strains NZB and F1 NZB×NZW. J Pathol Bacteriol 1966;91:467-76.
9. Esdaile JM, Federgreen W, Quintal H, Suissa S, Hayslett JP, Kashgarian M. Predictors of one year outcome in lupus nephritis: the importance of renal biopsy. Q J Med 1991;81:907-18.
10. Neumann K, Wallace DJ, Azen C, Nessim S, Fichman M, Metzger AL, et al. Lupus in the 1980s. III. Influence of clinical variables, biopsy, and treatment on the outcome in 150 patients with lupus nephritis seen at a single center. Semin Arthritis Rheum 1995;25:47-55.
11. Austin HA III, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-9.
12. Russell PJ, Hicks JD, Burnet FM. Cyclophosphamide treatment of kidney disease in (NZB × NZW) F1 mice. Lancet 1966;1:1280-4.
13. Morris AD, Esterly J, Chase G, Sharp GC. Cyclophosphamide protection in NZB/NZW disease: mechanisms and therapeutic regimens. Arthritis Rheum 1976;19:49-55.
14. Chia D, Levy L, Barnett EV, Carnes WH. Effects of pulse cyclophosphamide on NZB/W disease. Immunology 1981;43:57-65.
15. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994;265:1225-7.
16. Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol 1997;159:3104-8.
17. Mihara M, Tan I, Chuzhin Y, Reddy B, Budhai L, Holzer A, et al. CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus. J Clin Invest 2000;106:91-101.
18. Dixon FJ. The pathogenesis of murine systemic lupus erythematosus. [Rous-Whipple Award lecture]. Am J Pathol 1979;97:10-6.
19. Kashgarian M, Sterzel RB. The pathobiology of the mesangium. Kidney Int 1992;41:524-9.
20. Vlahakos DV, Foster MH, Adams S, Katz M, Ucci AA, Barrett KJ, et al. Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites. Kidney Int 1992;41:1690-700.
21. Clynes R, Dumitru C, Ravetch JV. Uncoupling of immune com-plex formation and kidney damage in autoimmune glomerulonephritis. Science 1998;279:1052-4.
22. Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999;189:1639-48.
23. Shlomchik MJ, Madaio MP, Ni D, Trounstein M, Huszar D. The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med 1994;180:1295-306.
24. Chan O, Shlomchik MJ. A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J Immunol 1998;160:51-9.
25. Bast RC Jr, Reinherz EL, Maver C, Lavin P, Schlossman SF. Contrasting effects of cyclophosphamide and prednisolone on the phenotype of human peripheral blood leukocytes. Clin Immunol Immunopathol 1983;28:101-14.
26. Bruijn JA, Dinklo NJ. Distinct patterns of expression of intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and endothelial-leukocyte adhesion molecule-1 in renal disease. Lab Invest 1993;69:329-35.
27. Yamada M, Yagita H, Inoue H, Takanashi T, Matsuda H, Munechika E, et al. Selective accumulation of CCR4+ T lymphocytes into renal tissue of patients with lupus nephritis. Arthritis Rheum 2002;46:735-40.
28. Ishikawa S, Sato T, Abe M, Nagai S, Onai N, Yoneyama H, et al. Aberrant high expression of B lymphocyte chemokine (BLC/ CXCL13) by C11b+/CD11c+ dendritic cells in murine lupus and preferential chemotaxis of B1 cells towards BLC. J Exp Med 2001;193:1393-402.